Mark Smith

Mark Smith, co-founder and CEO of Finch Therapeutics, leads the charge in microbiome therapeutics. He dives into how the microbiome influences immune function and its crucial role in overall health. Mark discusses the shift from traditional bacterial research to modern DNA techniques, emphasizing the need for balanced gut health. He also sheds light on innovative therapies like fecal transplants versus probiotics, and the challenges faced by biotech firms in this evolving landscape. Enjoy insights on transforming patient care through microbiome research!